Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDialysis/Renal ReplacementUnitedHealthcare Home Hemodialysis Coverage Update…
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy 2026T0476Y

    Home Hemodialysis (HHD) — Coverage Criteria

    Customize your policy alerts

    Sign up for UnitedHealthcare Policy 2026T0476Y alerts

    Get alerted when Policy 2026T0476Y changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and medical necessity criteria for home hemodialysis (with and without skilled care) for individuals with end-stage renal disease under UnitedHealthcare Commercial and Individual Exchange plans.

    Policy Summary
    PayerUnitedHealthcare
    PolicyHome Hemodialysis (HHD) — Coverage Criteria
    Policy CodePolicy 2026T0476Y
    Change TypeAdministrative template update
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain and document evidence of clinical stability, completed HHD training (CPT 90989 or 90993 per session), well‑functioning vascular access, and member-specific benefit verification when requesting prior authorization.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Template updated in the Policy History/Revision Information.

    3-4 hrstypical session length
    3x/weekcommon frequency
    90963-90970 etc.procedure codes
    3.76 vs 6.27mortality (HHD vs in-center)
    349 vs 1,047cohort size (Ok et al.)

    Coverage Criteria for Home Hemodialysis

    HHD without skilled care — medical necessity

    Covered when ALL of the following are met:

    HHD without skilled care criteria: Individual is stable on dialysis with no evidence of skilled care interventions being necessary during treatments.
    HHD without skilled care criteria: Individual undergoing hemodialysis or a non-professional caregiver has the ability to perform and maintain home hemodialysis and has received comprehensive training regarding proper protocol.
    HHD without skilled care criteria: Absence of complications and significant concomitant disease that would cause home hemodialysis to be unsafe or unsuitable.
    HHD without skilled care criteria: Individual has well-functioning vascular access.

    HHD with skilled care (staff-assisted) — medical necessity

    Covered when ALL of the following are met:

    Staff-assisted HHD criteria: Individual is stable on dialysis and not at increased risk as a result of having the procedure performed outside a dialysis center venue.
    Staff-assisted HHD criteria: Individual undergoing hemodialysis or non-professional caregiver is not capable of performing home hemodialysis.
    Staff-assisted HHD criteria: Individual has medical contraindications to leaving home for hemodialysis.
    Staff-assisted HHD criteria: Individual has well-functioning vascular access.
    Staff-assisted HHD criteria:

    Evidence summaries relevant to coverage

    Evidence summary relevant to coverage determinations

    survival benefit evidence: Observational cohort studies and meta-analyses report lower mortality associated with HHD or intensive HD regimens compared with conventional in-center HD (e.g., Ok et al. reported a 40% lower adjusted all-cause mortality in an ITT analysis; Mathew et al. and Miller et al. report associations of decreased mortality).

    Findings often derive from observational data subject to residual confounding; randomized trials are smaller and show mixed results.

    cardiovascular and surrogate outcomes: Randomized data (FHN Daily) demonstrated reductions in left ventricular mass and improved blood pressure control with frequent HD; FHN Nocturnal did not show significant benefit for co-primary outcomes. Pooled analyses note improved LV mass and related measures with more frequent HD.

    Effects on LV mass are plausibly mediated by improved volume and BP control.

    quality of life and recovery time: Frequent HD regimens showed improvements in patient-reported general health and shortened time to recovery after sessions in several studies and reviews, though results across QOL domains are variable.

    Self-reported measures may be biased by lack of blinding and younger, healthier study populations.

    Coverage for home hemodialysis requires that the patient be appropriate for treatment in the home setting. Individuals with complications or significant concomitant disease that would make home hemodialysis unsafe or unsuitable are not considered appropriate candidates until those issues are resolved. Similarly, a patient must have well‑functioning vascular access (for example, an arteriovenous fistula or other adequate access) because inadequate access or access‑related complications can increase infection and technical risk and therefore preclude safe HHD. These clinical exclusion considerations are part of the medical necessity determination and must be documented before authorizing HHD.

    The policy does not list discrete procedural exclusions, but clinical trial findings warrant caution for certain nocturnal or extended regimens. In the FHN Nocturnal trial (Rocco et al.), participants randomized to nocturnal hemodialysis experienced a higher mortality signal during extended follow‑up compared with the conventional arm; the study authors recommended cautious interpretation and further investigation. This observation supports careful patient selection and individualized risk assessment for nocturnal/extended regimens rather than blanket adoption.

    Guideline panels have noted that the evidence for some home long‑frequent regimens is inconclusive. The NKF/KDOQI Work Group reviewed available data and, given uncertainty about efficacy and signals for potential harm, stated that it could not make firm recommendations for home long frequent hemodialysis. This creates a cautionary context: lack of definitive guidance means clinicians and payers should weigh potential benefits against possible risks on a case‑by‑case basis.

    The document does not enumerate explicit conditions labeled as "not medically necessary." However, randomized trials show mixed results: some frequent‑HD trials report improvements in surrogate and patient‑reported outcomes while others—particularly the nocturnal trial—reported adverse signals such as higher mortality and increased vascular access procedures. These mixed trial results provide context for medical necessity decisions and support individualized assessment when considering nocturnal or intensified regimens.

    Procedure Codes, Devices, and Dosage Metrics

    Applicable procedure and per-diem codesmixed
    90963End-stage renal disease (ESRD) related services for home dialysis per full month, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents.
    90964End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents.
    90965End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents.
    90966End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 20 years of age and older.
    90967End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients younger than 2 years of age.
    90968End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 2-11 years of age.
    90969End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 12-19 years of age.
    90970End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 20 years of age and older.
    90989Dialysis training, patient, including helper where applicable, any mode, completed course.
    90993Dialysis training, patient, including helper where applicable, any mode, course not completed, per training session.
    1–10 of 12
    1/2
    FDA-cleared home hemodialysis devices (examples)mixed
    2008K @ home2008K @ home ™ Hemodialysis Machine (Fresenius Medical Care)
    NxStage System OneNxStage ® System One ™ (NxStage Medical, Inc.)
    NxStage VersiNxStage Versi ® HD with GuideMe software (NxStage Medical, Inc.)
    QuantaQuanta ™ Dialysis System (Quanta Dialysis Technologies, Ltd.)
    TabloTablo ® Hemodialysis System (Outset Medical, Inc.)
    spKt/V per session
    NKF/KDOQI target per sessionTarget spKt/V 1.4 per hemodialysis session (thrice-weekly)
    Minimum delivered spKt/VMinimum delivered spKt/V 1.2 per session
    Context of useApplies to thrice-weekly hemodialysis adequacy recommendations

    Provider Actions, Documentation, and Authorization

    Prior Authorization

    Prior authorization may be required for HHD-related codes

    Prior authorization may be required for home hemodialysis services billed with the listed ESRD, training, home-visit, and per-diem home therapy codes; coverage is contingent on meeting the policy's medical necessity criteria.

    • Codes listed: 90963–90970 (ESRD home dialysis monthly/day), 90989 (dialysis training completed), 90993 (training per session, course not completed), 99512 (home visit for hemodialysis), S9335 (home therapy per diem).
    • Ensure medical necessity criteria in the policy are met when requesting authorization.
    Note

    Evidence elements that may be requested

    Be prepared to provide device- and regimen-specific efficacy and safety data during review, including trial-level outcomes and predefined endpoints reported in device studies.

    • Efficacy endpoints: weekly standard Kt/Vurea (e.g., ≥ 2.1), average weekly stdKt/V, spKt/V targets/delivery.

    Background — Hemodialysis and Home Therapies

    Hemodialysis (HD) is an extracorporeal renal replacement therapy that removes fluid and small‑molecule waste products by circulating blood through a dialyzer. Conventional in‑center HD is typically delivered three times per week for about 3–4 hours per session. Home hemodialysis (HHD) permits delivery of dialysis in the patient’s residence using home‑capable machines and requires patient and/or caregiver training, adequate home setup, and reliable vascular access; HHD prescriptions may vary in frequency and duration but must be individualized by the treating nephrologist.

    Definitions and Key Terms

    Arteriovenous fistula (AVF)
    DefinitionA surgically created connection between an artery and a vein used as vascular access for hemodialysis (HD)
    Clinical noteArteriovenous fistulas (AVFs) are considered the 'gold standard' access because they are associated with far fewer complications than grafts or indwelling catheters
    Patient counselingIndividuals performing HHD should be encouraged and trained to use AVF needlesticks despite initial apprehension; catheters carry higher infection risk
    Home hemodialysis (HHD)
    DefinitionHemodialysis performed in a patient's home environment using a home-capable dialysis system
    System characteristicsHome-capable systems are more user-friendly than in-center machines and include safety features to minimize complications

    Policy Revision History

    2026-01-01administrativeLatest

    Template update to the Policy History/Revision Information; no clinical coverage changes stated.

    Policy Summary
    PayerUnitedHealthcare
    PolicyHome Hemodialysis (HHD) — Coverage Criteria
    Policy CodePolicy 2026T0476Y
    Change TypeAdministrative template update
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain and document evidence of clinical stability, completed HHD training (CPT 90989 or 90993 per session), well‑functioning vascular access, and member-specific benefit verification when requesting prior authorization.
    SourceLink
    On This Page
    Coverage Criteria for Home HemodialysisProcedure Codes, Devices, and Dosage MetricsProvider Actions, Documentation, and AuthorizationBackground — Hemodialysis and Home TherapiesDefinitions and Key TermsPolicy Revision History
    Staff-assisted home hemodialysis protocols generally match those provided in the hemodialysis center (i.e., 3 times per week, 3-4-hour treatments); the exact dialysis therapy employed is determined on an individual basis by the attending nephrologist.
    safety and harms: Frequent or intensive HD is associated with increased vascular access interventions and intradialytic hypotension in several trials; nocturnal HHD in one randomized trial showed higher long-term mortality and accelerated loss of residual renal function in extended follow-up analyses.

    Adverse event signals vary by regimen and study; small sample sizes limit inference.

    device-specific data: A small prospective nonrandomized crossover device study (Tablo system) demonstrated achievement of adequacy targets (e.g., stdKt/V), acceptable ultrafiltration delivery, and similar patient-reported outcomes between in-center and home periods without device-related adverse events, but sample size and duration were limited.

    Device-level evidence may inform coverage but is limited by study design and size.

  1. Ultrafiltration delivery metrics: percentage of treatments with UF delivered within 10% of prescribed UF.
  2. Safety endpoints: prespecified adverse events (number and relatedness), vascular access interventions, intradialytic hypotension.
  3. Patient-reported outcomes and trial results: time to recovery (TTR), general health status (EQ-5D), sleep quality, randomized trial composite outcomes and mortality data.
  4. Note

    Prior authorization governed by member plan

    This policy is informational and does not itself prescribe prior authorization codes, processes, or requirements; verify prior authorization rules with the member's specific benefit plan and any applicable tools UnitedHealthcare may use.

    • Member-specific benefit plan governs in the event of conflict with this policy.
    • UnitedHealthcare may use third-party tools (e.g., InterQual) to assist in administering benefits.
    Documentation Required

    Document clinical justification aligned to policy criteria

    When initiating or changing to HHD, document clinical justification that aligns with policy criteria and the member's plan, including stability on dialysis, training status, vascular access function, and any medical contraindications to in-center dialysis.

    • State whether HHD is being requested with or without skilled care and reference the corresponding medical necessity criteria.
    • Record consideration of member-specific benefit plan terms and applicable federal/state mandates.
    Step Therapy

    No step therapy specified

    No step therapy mandates are specified in this policy.

    • Providers should still verify member-specific plan rules for any plan-level step therapy requirements.
    Documentation Required

    Minimum documentation expectations

    Maintain documentation that supports the member meets minimum policy expectations for HHD initiation or continuation.

    • Evidence of clinical stability on dialysis (notes showing no need for skilled interventions during treatments).
    • Training records: CPT 90989 for completed dialysis training course or CPT 90993 per training session if course incomplete.
    • Confirmation of well-functioning vascular access documented in clinical notes.
    • If staff-assisted HHD is requested, documentation of medical contraindications to leaving home and rationale for skilled care.
    Documentation Required

    Suggested documentation elements from device study

    From device studies, document predefined safety and efficacy endpoints that support home use of a specific HHD system.

    • Weekly standard Kt/Vurea results (e.g., proportion of measurements ≥ 2.1 and mean weekly stdKt/V).
    • Ultrafiltration delivery performance (e.g., percent of treatments with UF within 10% of prescribed UF).
    • Number and description of prespecified adverse events and assessment of relatedness to the device.
    • Patient-reported outcomes: time to recovery (TTR), EQ-5D general health scores, sleep quality measures.
    • Study context: sample size, duration, and participant age distribution to assess generalizability.
    Documentation Required

    Document plan-specific verification

    Verify and document review of the member-specific benefit plan and any applicable federal or state mandates before applying this policy to a coverage decision.

    • Record the member-specific plan document reference and note any applicable mandates or exceptions.
    • If conflicts exist between this policy and the member's plan, the member-specific benefit plan governs—document how the conflict was resolved.
    Denial Risk

    Denial triggers for HHD coverage

    Coverage may be denied if the member does not meet the policy's medical necessity criteria or if safety concerns exist for home therapy.

    • Not stable on dialysis or requires skilled care interventions during treatments.
    • Individual or caregiver lacks ability or training to perform and maintain HHD.
    • Presence of complications or significant concomitant disease that make HHD unsafe or unsuitable.
    • Lack of well-functioning vascular access.
    Note

    Study limitations that may affect coverage

    Study limitations may affect extrapolation of safety and efficacy to broader populations and could influence coverage decisions.

    • Small sample sizes and brief study periods limit confidence in long-term outcomes.
    • Participants in device studies were on average younger than typical U.S. dialysis populations, reducing generalizability.
    Note

    Reference member-specific benefits

    Always reference the member-specific benefit plan document and applicable federal or state mandates when determining coverage; in the event of a conflict, the member-specific plan governs.

    • Document the benefit plan used to make the decision and note any deviations from this policy based on plan terms.
    • Check for Medicare NCDs/LCDs or other applicable coverage guidance when relevant (Medicare MA applicability noted).
    Training requirementRequires comprehensive training for the patient and/or caregiver and suitable home setup prior to initiation
    Usual care / conventional HD
    DefinitionIn-center hemodialysis provided three times per week with session lengths typically less than 4 hours
    Typical session lengthConventional sessions are usually 3-4 hours per treatment
    SettingDelivered in a dialysis center on a schedule determined by the facility
    More frequent HD
    DefinitionHemodialysis regimen consisting of four or more treatments per week
    Evidence noteMore frequent HD has low strength of evidence for benefits like reduced LV mass and improved BP but may increase vascular access complications
    Common settingMay be delivered in-center or at home; many frequent HD programs in the U.S. are home-based
    Longer HD
    DefinitionDialysis sessions with duration of 4 or more hours per treatment
    NKF/KDOQI considerationHome long hemodialysis (6-8 hours, 3-6 nights/week) is an option for patients who prefer this therapy
    Clinical rationaleLonger treatments may be considered for patients with large interdialytic weight gains, high ultrafiltration rates, or poor metabolic control
    spKt/V
    DefinitionSingle-pool Kt/V (spKt/V) is a measure of dialysis dose reflecting urea clearance per session
    NKF/KDOQI targetRecommend a target spKt/V of 1.4 per hemodialysis session for patients treated thrice weekly
    Minimum deliveredRecommend a minimum delivered spKt/V of 1.2 per session
    510(k) clearance
    DefinitionFDA 510(k) clearance is a premarket notification indicating a device is substantially equivalent to a legally marketed device and cleared for marketing
    Examples of 510(k)-cleared HHD devices2008K @ home (Fresenius), NxStage System One, NxStage Versi HD with GuideMe, Quanta Dialysis System, Tablo Hemodialysis System
    Policy noteFDA clearance is informational only and does not by itself determine coverage